CKD BiO

Botulinum toxin formulated without human serum albumin (HSA) and with L-histidine; it holds Halal certification and was launched in Korea in July 2025.

Botulinum toxin in development for China (code CU-20101); its Chinese Phase 3 trial showed non-inferiority to Botox for glabellar lines.

Fermentation- and synthesis-based APIs: 14 listed products including antibiotics, beta-lactamase inhibitors, immunosuppressants such as tacrolimus and everolimus, diquafosol for dry eye and diabetes drugs.

A line of 25 Lactobacillus and Bifidobacterium probiotic products made with the company's 50 years of fermentation know-how.

GMP plants in Ansan, Gyeonggi-do (API plant, 51,473 m2), Osong in Cheongju, Chungcheongbuk-do, and Yesan, Chungcheongnam-do, which also serve CMO/CDMO customers.

Reported Chinese Phase 3 results comparing 278 patients on CU-20101 with 275 on Botox: glabellar line response rates were 74.0% versus 74.9%, meeting non-inferiority.

Held a symposium for physicians in Seoul on 11 July 2026 to mark the first anniversary of the TYEMVERS launch.

Its U.S. partner received FDA clearance for a Phase 1 trial of TYEMVERS for major depressive disorder; CKD BiO manufactures and supplies the investigational product.